Home/ Stocks/ ALXO

ALX Oncology Holdings Inc. Common Stock

ALXO XNAS

$2.10 +0.00 (+0.00%) ▲ 15-min delayed

Open

$2.13

High

$2.18

Low

$2.04

Volume

8.49M

Market Cap

$283.93M

About ALX Oncology Holdings Inc. Common Stock

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 43 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-17,927,000	$-0.17
FY 2025	$0	$-101,695,000	$-1.90
Q3 2025	$0	$-22,144,000	$-0.41
Q2 2025	$0	$-25,949,000	$-0.49

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 5, 2026

Calendar →

Related Market News

No specific coverage for ALXO yet. Check out our latest market news or earnings calendar.

Get ALXO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on ALX Oncology Holdings Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.